<DOC>
	<DOCNO>NCT03070704</DOCNO>
	<brief_summary>This study conduct Asia . The aim study evaluate long term safety efficacy patient type 2 diabetes mellitus routine clinical practice India .</brief_summary>
	<brief_title>Non-interventional , Post Marketing Surveillance Study Xultophy™ ( Insulin Degludec/Liraglutide ) Evaluate Long Term Safety Efficacy Patients With Type 2 Diabetes Mellitus Routine Clinical Practice India</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain studyrelated activity . Studyrelated activity procedure relate record data determine suitability study accord protocol . Some specific historical data collect informed consent obtain used baseline data ( HbA1c , FPG/FBG others ) The decision initiate treatment commercially available Xultophy™ make patient/Legally Acceptable Representative ( LAR ) treat physician independently decision include patient study Male female , age least 18 year time signing informed consent Patients diagnose type 2 diabetes mellitus Patients schedule start treatment Xultophy™ base clinical judgement treat physician Known suspect hypersensitivity Xultophy™ , active substance , excipients related product Previous participation study . Participation define sign informed consent Mental incapacity , unwillingness language barrier hinder adequate understanding cooperation Females pregnant , breastfeed intend become pregnant within follow 12 month Patients participate study clinical trial . Any disorder opinion Physician might jeopardise subject 's safety compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>